CILNIDIPINE

Atelec; Cinalong; Siscard; (+-)-(E)-Cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; O3-(2-Methoxyethyl) O5-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl (2E)-3-phenyl-2-propenyl ester;

CILNIDIPINE

 

PRODUCT IDENTIFICATION

CAS RN

132203-70-4

EINECS RN

 

FORMULA

C27H28N2O7

MOLE WEIGHT

492.52

 

PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL STATE

light yellowish powder

MELTING POINT

107 - 112 C

BOILING POINT

 

DENSITY

 

SOLUBILITY IN WATER

 

pH

 

VAPOR DENSITY

 

REFRACTIVE INDEX

 

FLASH POINT

 

 

STABILITY AND REACTIVITY
STABILITY Stable under normal conditions. Light may affect product.

INCOMPATIBLE MATERIALS

Strong oxidizing agents.

DECOMPOSITION PRODUCTS carbon oxides, nitrogen oxides.
POLYMERIZATION Has not been reported

NFPA RATINGS

Health: 2, Flammability: 0, Reactivity: 0

 

SAFETY

HAZARD NOTES

Irritant. Risk of serious damage to eyes.

EYE

Causes eye irritation.

SKIN

Causes skin irritation. May be harmful if absorbed through the skin.

INGESTION

Harmful if swallowed.

INHALATION

Material is irritating to mucous membranes and upper respiratory tract. May be harmful if inhaled.

CHRONIC

 

 

TRANSPORT & REGULATORY INFORMATION

UN NO.

 
HAZARD CLASS

 

PACKING GROUP

 

HAZARD SYMBOL

XI

RISK PHRASES

41

SAFETY PHRASES

26-39

 

EXTERNAL LINKS & GENERAL INFORMATION
N-Type calcium channel antagonists may suppress sympathetic activity. The purpose of this study was to assess the effects of amlodipine and cilnidipine on the cardiac sympathetic nervous system and the neurohormonal status of essential hypertension. I-metaiodobenzylguanidine (MIBG) cardiac imaging was performed and blood samples were taken to determine plasma renin activity and plasma norepinephrine concentration before and 3 months after drug administration in 47 patients with mild essential hypertension. Twenty-four of the patients were treated with 5 to 10 mg/d of amlodipine; the other 23 were treated with 10 to 20 mg/d of cilnidipine. For comparison, 12 normotensive subjects were also studied. No significant differences were found in the basal characteristics between the 2 hypertensive groups. In both hypertensive groups, both the systolic and diastolic blood pressures were significantly reduced to similar levels 3 months after drug treatment. Before the drug treatment, the 2 hypertensive groups had a significantly higher washout rate and lower heart-to-mediastinum (H/M) ratio compared with the normotensive subjects. The H/M ratio significantly increased (P<0.05) in combination with a decreased washout rate (P<0.02) after drug treatment in the cilnidipine group. In the amlodipine group, a significant decrease in washout rate (P<0.04) was noted, without an increase in the H/M ratio. However, no significant changes were found in plasma renin activity and plasma norepinephrine concentration in either group. Thus, in patients with essential hypertension, cilnidipine suppressed cardiac sympathetic overactivity and amlodipine had a little suppressive effect. Cilnidipine may provide a new strategy for treatment of cardiovascular diseases with sympathetic overactivity. ( http://hyper.ahajournals.org/)

Calcium channel blockers

Product

CAS RN

1,4-Dihydropyridine 3337-17-5
2-(4-(Dimethylamino)styryl)-1-methylpyridinium 2156-29-8
8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate 57818-92-5
Amlodipine 88150-42-9
Mix(Amlodipine besylate, Benazepril hydrochloride) 858669-53-1
Anandamide 94421-68-8
Anipamil 83200-10-6

Aranidipine

86780-90-7

Azelnidipine

123524-52-7
Azimilide 149908-53-2
Barnidipine hydrochloride 104757-53-1
Barnidipine 104713-75-9
Belfosdil 103486-79-9
Bencyclane 2179-37-5
Benidipine 105979-17-7
Bepridil 64706-54-3
Berbamine 478-61-5
Bevantolol 59170-23-9
Canadine 522-97-4
Carboxyamidotriazole 99519-84-3
Cilnidipine 132203-70-4
Cinnarizine 298-57-7
Clentiazem 96125-53-0

Clevidipine

166432-28-6
Darodipine 72803-02-2
Dauricine 524-17-4
Devapamil 92302-55-1

Dihydropyridine

27790-75-6
Diltiazem 42399-41-7

Diproteverine

69373-95-1

Diproteverine HCl

69373-88-2
Dotarizine 84625-59-2
Efonidipine 111011-63-3
Emopamil 78370-13-5
Enpiperate 3608-67-1
Eperisone 64840-90-0
Falipamil 77862-92-1
Fantofarone 114432-13-2
Fasudil 103745-39-7
Felodipine 72509-76-3
Fenamic acid 91-40-7
Fendiline 13042-18-7
Flunarizine 52468-60-7
Fostedil 75889-62-2
Gabapentin 60142-96-3
Gallopamil 16662-47-8
N-(2-Guanidinoethyl)-5-isoquinolinesulfonamide 91742-10-8
Inamrinone 60719-84-8
Isradipine 75695-93-1
Lacidipine 103890-78-4
Lamotrigine 84057-84-1
Lercanidipine 100427-26-7
Lercanidipine hydrochloride 132866-11-6
Lidoflazine 3416-26-0
Lomerizine dihydrochloride 101477-54-7
Magnesium sulfate 7487-88-9
Manidipine 89226-50-6
Manoalide 75088-80-1
Mibefradil dihydrochloride 116666-63-8
Monatepil 103379-03-9
Naftopidil 57149-07-2
Nicardipine 55985-32-5
Nifedipine 21829-25-4
Niguldipine 102993-22-6
Niludipine 22609-73-0
Nilvadipine 75530-68-6
Nimodipine 66085-59-4
Nisoldipine 63675-72-9
Nitrendipine 39562-70-4
Norverapamil 67018-85-3
Ochratoxin A 303-47-9
omega-Agatoxin IVA 145017-83-0
omega-Conotoxin G VIA 92078-76-7
omega-Conotoxin-mviic 147794-23-8
Osthol 484-12-8
Otilonium bromide 26095-59-0
Oxodipine 90729-41-2
Perhexiline 6621-47-2
Pinaverium 59995-65-2
Piperidine 110-89-4
Pranidipine 99522-79-9
Prenylamine 390-64-7
N-(1-(4-(4-Fluorophenoxy)butyl)-4-piperidinyl)-N-methyl-2-benzothiazolamine 104606-13-5
Riodipine 71653-63-9
Risedronic acid 105462-24-6
Sesamodil 116476-14-3
1-(2-(3-(4-Methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole HCl 130495-35-1
Stepholidine 16562-13-3
Temiverine 173324-94-2
Terodiline 15793-40-5
Tetrahydropalmatine 10097-84-4
Tetrandrine 518-34-3
Tiapamil HCl 57010-32-9
Tolfenamic acid 13710-19-5
Tranilast 53902-12-8

Verapamil

52-53-9

Watanidipine 116308-55-5
Ziconotide 107452-89-1

 

SALES SPECIFICATION

APPEARANCE

light yellowish powder

ASSAY

98.0 - 101.0%

MELTING POINT

107 - 112 C

HEAVY METALS

20ppm max

LOS ON DRYING

0.5% max

RESIDUE ON IGNITION

0.1% max

 

PACKING

 

 

PRICE

click to open the table

 

Clik to close the table